Characteristics of patients in the SLICC Inception Cohort over first 2 years*
| Enrolment | Year 1 | Year 2 | |
|---|---|---|---|
| No. of patients | 1150 | 823 | 686 |
| Age (years) (mean (SD)) | 34.9 (13.6) | 36.2 (13.7) | 37.2 (13.9) |
| Gender (%) | |||
| Women | 1036 (90.1) | 729 (88.6) | 608 (88.6) |
| Race/ethnicity (%) | |||
| Caucasian | 516 (44.9%) | 399 (48.5) | 347 (50.6%) |
| Indian subcontinent | 37 (3.2) | 39 (4.7) | 21 (3.1) |
| Black African | 79 (6.9) | 49 (6.0) | 50 (7.3) |
| Afro-Caribbean | 75 (6.5) | 61 (7.4) | 41 (6.0) |
| Korean | 151 (13.2) | 106 (12.9) | 67 (9.8) |
| Hispanic | 182 (15.9) | 89 (10.8) | 83 (12.1) |
| Other | 108 (9.4) | 80 (9.7) | 77 (11.2) |
| CHD risk factors (mean (SD)) | |||
| BP systolic (mm Hg) | 118.5 (16.4) | 117.5 (16.8) | 117.8 (16.3) |
| BP diastolic (mm Hg) | 74.7 (10.7) | 73.9 (10.5) | 73.5 (10.6) |
| On AHT medication (%) | 328 (28.5) | 259 (31.5) | 246 (35.9) |
| Total cholesterol (mmol/L) | 4.89 (1.50) | 4.59 (1.11) | 4.57 (1.12) |
| Triglyceride (mmol/L) | 1.78 (1.21) | 1.45 (1.1) | 1.39 (0.95) |
| HDL-cholesterol (mmol/L) | 1.39 (0.61) | 1.44 (0.49) | 1.43 (0.47) |
| Lipid-lowering medication (%) | 168 (14.6) | 138 (16.8) | 124 (18.1) |
| Glucose (mmol/L) | 5.02 (1.71) | 4.78 (1.00) | 4.74 (1.05) |
| Smoker current (%) | 169 (14.7) | 113 (13.8) | 97 (14.2) |
| Premenopausal (%) | 813 (70.6) | 558 (67.8) | 464 (67.6) |
| BMI | 24.8 (5.9) | 25.4 (5.9) | 25.2 (6.1) |
| WC (cm) | 82.0 (14.0) | 83.3 (14.9) | 82.3 (14.5) |
| SLEDAI (mean (SD)) | 5.4 (5.2) | 3.7 (41) | 3.7 (4.2) |
| SLICC/ACR-DI≥1 (%) | 97/504 (19.3) | 215/815 (26.4) | 208/679 (30.6) |
| Disease phenotype (%) | |||
| Active renal disease | 261 (22.8) | 132 (16.2) | 93 (13.6) |
| Anti-dsDNA positive | 427/1034 (41.3) | 262/766 (34.2) | 227/672 (33.8) |
| Low complement | 419/1038 (40.4) | 273/766 (35.6) | 229/672 (34.1) |
| Oral CS use (%) | 796 (69.2) | 581 (70.6) | 401 (58.5) |
| Oral CS dose (median (IQR)) | |||
| Average CS dose(mg) | 20 (10, 34) | 10 (7, 15) | 8.0 (5, 12.5) |
| Highest CS dose(mg) | 40 (20, 60) | 20 (10, 40) | 10 (5, 20) |
| Cumulative CS dose (g) | 2.6 (1.0, 5.0) | 3.8 (2.5, 6.1) | 5.6 (3.7, 8.9) |
| Pulse IV CS (%) | 52/1095 (4.9) | 57/819 (7.0) | 24/683 (3.5) |
| Immunosuppressant use (%) | 464 (40.4) | 337 (41.0) | 299 (43.6) |
| Azathioprine | 196 (43.7) | 141 (42.0) | 126 (42.3) |
| Methotrexate | 104 (17.4) | 62 (18.6) | 63 (21.1) |
| Mycophenolate mofetil | 98 (16.4) | 65 (19.5) | 59 (19.6) |
| IV cyclophosphamide | 95 (15.9) | 35 (10.4) | 29 (9.9) |
| Cyclosporin | 21 (3.5) | 16 (4.7) | 14 (4.8) |
| Other | 19 (3.2) | 17 (4.1) | 8 (2.6) |
| Antimalarial use (%) | 759 (66.0) | 555 (67.4) | 483 (70.4) |
*Denominator is the total patient number unless stated otherwise.
ACR, American College of Rheumatology; AHT, antihypertensive; BMI, body mass index; BP, blood pressure; CHD, coronary heart disease; CS, corticosteroid; HDL, high density lipoprotein; IV, intravenous; SLEDAI, Systemic Lupus Erythematosus Disease Activity index; SLICC, Systemic Lupus Erythematosus International Collaborating Clinics; WC, waist circumference.